推荐产品
生物来源
human
质量水平
重组
expressed in E. coli
方案
>98% (SDS-PAGE and HPLC)
表单
solid
分子量
19.6 kDa
制造商/商品名称
Chemicon®
技术
cell culture | mammalian: suitable
杂质
<0.1 ng/μg Endotoxin (of TRAIL/Apo2L; 1EU/μg)
输入
sample type hematopoietic stem cell(s)
适用性
suitable for molecular biology
NCBI登记号
UniProt登记号
运输
dry ice
基因信息
human ... TNFSF10(8743)
一般描述
Research area: CancerTNF-Related Apoptosis-Inducing Ligand (TRAIL) is a cytotoxic and type II membrane protein. It belongs to the tumor necrosis factor (TNF) superfamily. TRAIL is expressed by the cells of the immune system including natural killer cells, macrophages, T cells, and dendritic cells. TRAIL Protein, Recombinant human is a 19.6 kDa protein
应用
TRAIL Protein, Recombinant human has been used as anapoptosis inducer: to extract cell-free DNA (cfDNA) from various cell linesalong with BV6 to study its anticancer effects in breast cancer cell lines, tostudy its effects of ethanol-induced interferon expression on TRAIL release in neurons
生化/生理作用
TNF-Related Apoptosis-Inducing Ligand (TRAIL) promotes rapid apoptosis in tumor cells while sparing normal cells. Thisproperty of TRAIL makes it an important biotherapeutic agent in cancer therapy.It induces apoptosis by binding to two death signaling receptors, DR4 and DR5expressed on cell membranes.
外形
无菌过滤,然后从 0.3 mg/mL(含 10mM 磷酸钠 + 110mM NaCl)溶液中冻干。
储存及稳定性
冻干的蛋白可以在室温下保存数周,但最好在 -20°C 下保存。 快速离心后,在无菌水中重新配制至 0.5-1.0 mg/mL。 可以将该溶液稀释到其他缓冲溶液中,并在 4ºC 下保存 1 周或 -20ºC 以备将来使用。 自收到之日起,重悬的 GF092 应该以未稀释的等分试样在 -20°C 下保存长达 6 个月。应避免反复冻/融循环。
法律信息
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
免责声明
除非我们的产品目录或产品附带的其他公司文档另有说明,否则我们的产品仅供研究使用,不得用于任何其他目的,包括但不限于未经授权的商业用途、体外诊断用途、离体或体内治疗用途或任何类型的消费或应用于人类或动物。
储存分类代码
11 - Combustible Solids
WGK
WGK 3
Cancer letters, 263(1), 14-25 (2008-03-11)
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptors are promising targets for the selective eradication of tumor cells while sparing normal cells. Currently, both recombinant TRAIL proteins and TRAIL receptor agonistic antibodies are being tested in the clinic, showing encouraging antitumor
The clinical trail of TRAIL
European Journal of Cancer, 42(14), 2233-2240 (2006)
Molecular cancer therapeutics, 19(12), 2585-2597 (2020-11-18)
Complexities in treating breast cancer with bone metastasis are enhanced by a vicious protumorigenic pathology, involving a shift in skeletal homeostasis toward aggressive osteoclast activity and polarization of immune cells supporting tumor growth and immunosuppression. Recent studies signify the role
Biology, 11(11) (2022-11-12)
Cancer is the utmost common disease-causing death worldwide, characterized by uncontrollable cell division with the potential of metastasis. Overexpression of the Inhibitors of Apoptosis proteins (IAPs) and autophagy correlates with tumorigenesis, therapeutic resistance, and reoccurrence after anticancer therapies. This study
Communications biology, 7(1), 441-441 (2024-04-11)
Clinical circulating cell-free DNA (cfDNA) testing is now routine, however test accuracy remains limited. By understanding the life-cycle of cfDNA, we might identify opportunities to increase test performance. Here, we profile cfDNA release across a 24-cell line panel and utilize
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门